The Scottish Medicines Consortium (SMC) has invited Revive MS Support to participate in giving feedback on a new medicine which is aimed at “Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features”.
The medicine is ofatumumab (Kesimpta) and the company which produces it is seeking license for its use in Scotland. This medicine is “unique in offering people with RMS a high-efficacy treatment with a manageable safety profile that can be self-administered at home”. “Ofatumumab is given via injection under the skin (subcutaneous) which patients can do at home”.
The SMC is keen to hear our clients’ views, thoughts, concerns, and so a Focus Group will be hosted by Margaret Campbell, Clinical Manager via Zoom Web link on Tuesday 27th April from 11:30 – 1:30.
Should you wish to participate in this discussion please contact Margaret via e-mail and she will send you details of the Zoom link.
Please note that this Zoom call will be recorded, with permission sought from participants. The recording will not be shared with the SMC; it is only to ensure that all views are captured when Margaret submits a report to the SMC.